Galapagos huge outperformer in European biotech sector

In the past years Galapagos was a very good choice for investors. The stock was the past 5 years with a return of 543 percent one of the larger outperformers of her peer group. Shares of the peer group delivered the past 5 years a gain of at around 237 percent. Other strong winning shares of the sector are Pharming , Assembly Biosciences and Catalyst Pharmaceutical Partners. Assembly Biosciences, Catalyst Pharmaceutical Partners and Pharming are some of the winning stocks in the sector.

Momentum biotech sector

fundamental data For the average share in the sector around 4 times the earnings per share is paid. The sector trades at 2,28 times the book value per share. The returns since 2007 are +423 percent and since 2012 +237 percent.

Over the current book year the total revenue will be 238,63 million euros (consensus estimates). This is quite more than 2017's revenue of 155,92 million euros.

Historical revenues and results Galapagos plus estimates 2018

stock graphs

The analysts expect for 2018 a net loss of 124 million euros. According to most of the analysts the company will have a loss per share for this book year of 2,44 euros. Based on this the price/earnings-ratio is -37,8.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a limited 0,5 percent.

Most recent target prices around 115 euros

The most recent recommendations for the biotech company are from JP Morgan, Credit Suisse and InsingerGilissen.

Galapagos 's market value equals around 4,27 billion . The Galapagos stock was the past 12 months quite unstable. Since last November the stock is 10 percent higher. This year the stock price moved between 71 and 105 euro. Since 2008 the stock price is almost 2290 percent higher.

Historical stock prices Galapagos

stock graphs galapagos

At 17.35 the stock trades 1,5 percent lower at 92,24 euros.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.